Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza
drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a …

Abstract Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent
that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA …

Abstract The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need …

Favipiravir, also known as T-705, is an antiviral drug that has been approved in 2014 in
Japan to treat pandemic influenza virus infections. The drug is converted intracellularly into …

Eight different compounds, all nucleoside analogues, could presently be considered as
potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic …

The RNA polymerase inhibitor favipiravir is currently in clinical trials as a treatment for
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), despite …

During the last forty years we have witnessed impressive advances in the field of antiviral
drug discovery culminating with the introduction of therapies able to stop human …

Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in
clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a …

Antiviral drug resistance is a matter of great clinical importance that, historically, has been
investigated mostly from a virological perspective. Although the proximate mechanisms of …

The 2014–2015 outbreak of Ebola virus disease is the largest epidemic to date in terms of
the number of cases, deaths, and affected areas. In October 2015, no antiviral agents had …